Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Prague Med Rep ; 122(2): 80-95, 2021.
Article in English | MEDLINE | ID: mdl-34137684

ABSTRACT

Determination of renin plasma levels is useful in the diagnosis of hypertension and in the therapeutic follow-up of hypertensive patients. Plasmatic concentration of renin decreases in patients with hypertension due to a primary hyperaldosteronism, contrary to renovascular hypertension where concentrations of renin and aldosterone are both elevated. Blood samples (serum, EDTA plasma) were analysed using two different chemiluminiscent methods CLIA LIAISON® and radioimmunoassay for aldosterone (IMMUNOTECH Beckman Coulter) and renin (Cisbio Bioassay) measurements were compared. We used both methods to ascertain the correlation between serum vs. EDTA plasma levels of aldosterone (RIA, CLIA) and renin (IRMA, CLIA) and to compare aldosterone to renin ratios for CLIA and for radioimmunoassay: serum aldosterone to plasma renin and plasma aldosterone to plasma renin. We compared serum aldosterone CLIA vs. RIA (rP=0.933, P<0.001) and plasma renin determined using CLIA vs. IRMA (rP=0.965, P=0.062). Furthermore, we used both methods to establish the correlation between the serum vs. plasma levels of aldosterone: RIA (rP=0.980, P<0.001); CLIA (rP=0.994, P=0.353) and serum vs. plasma levels of renin: IRMA (rP=0.948, P<0.001); CLIA (rP=0.921, P=0.011). Aldosterone (serum, plasma) to plasmatic renin ratios for CLIA (rP=0.999, P=0.286) and for radioimmunoassay (rP=0.992, P=0.025). Our data demonstrate that renin and aldosterone concentrations obtained using CLIA correlate with renin and aldosterone concentrations using radioimmunoassay methods. Correlation coefficients of pair results ranged from 0.921 to 0.994. Aldosterone (serum, EDTA plasma) to plasmatic renin ratios are comparable and any of them can be used with no significant differences found.


Subject(s)
Aldosterone , Hyperaldosteronism , Humans , Luminescence , Radioimmunoassay , Renin
2.
Pancreatology ; 17(1): 89-94, 2017.
Article in English | MEDLINE | ID: mdl-28027898

ABSTRACT

BACKGROUND: The changes in gastrointestinal hormones associated with pancreatic ductal adenocarcinoma (PDAC) in patients with impaired glucoregulation have yet to be evaluated. The aim of this study was to determine plasma concentrations of selected gastrointestinal hormones in PDAC patients with and without diabetes and to compare them with levels found in Type 2 diabetic patients without cancer. METHODS: In this study we examined plasma concentrations of glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), pancreatic polypeptide (PP), peptide YY (PYY) and neuropeptide Y (NPY), and cytokines leptin and adiponectin in 94 patients with histologically confirmed PDAC. Thirty-nine patients with Type 2 diabetes without PDAC and 29 healthy individuals with no evidence of acute or chronic diseases were examined as controls. RESULTS: Significantly lower plasma concentrations of GIP were found in PDAC patients with new-onset diabetes/prediabetes (n = 76), or in those with normal glucose regulation (n = 18), compared to patients with Type 2 diabetes without PDAC and controls (15.5 (3.7-64.5) or 6.5 (1.7-24.5) vs. 39.8 (15.1-104.7) and 28.8 (7.4-112.2) ng/L, p < 0.001); the same relationship was observed for PP (38.9 (10.2-147.9) or 28.1 (7.9-100.0) vs 89.1 (38.0-208.9) and 75.8 (30.1-190.6) ng/L, p < 0.01), respectively. The lowest levels of GIP and PP concentrations were found in PDAC patients with new-onset diabetes/prediabetes and weight loss > 2 kg (p < 0.001). CONCLUSIONS: We conclude that GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. In new onset diabetes especially if associated with weight loss, these changes may represent a new clue for the diagnosis of PDAC.


Subject(s)
Blood Glucose/metabolism , Carcinoma, Pancreatic Ductal/blood , Diabetes Mellitus, Type 2/complications , Gastric Inhibitory Polypeptide/blood , Pancreatic Neoplasms/blood , Pancreatic Polypeptide/blood , Weight Loss , Adult , Aged , Biomarkers/blood , Carcinoma, Pancreatic Ductal/complications , Carcinoma, Pancreatic Ductal/diagnosis , Carcinoma, Pancreatic Ductal/physiopathology , Case-Control Studies , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/physiopathology , Female , Glucagon-Like Peptide 1/blood , Glucose Intolerance/blood , Glucose Intolerance/complications , Glucose Intolerance/physiopathology , Humans , Male , Middle Aged , Neuropeptide Y/blood , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/physiopathology , Peptide YY/blood
3.
Neuropsychiatr Dis Treat ; 10: 675-9, 2014.
Article in English | MEDLINE | ID: mdl-24851049

ABSTRACT

Recent evidence indicates that the nature of interactions between the nervous system and immune system is important in the pathogenesis of depression. Specifically, alterations in pro-inflammatory cytokines have been related to the development of several psychological and neurobiological manifestations of depressive disorder, as well as to stress exposure. A number of findings point to tumor necrosis factor alpha (TNF-α) as one of the central factors in these processes. Accordingly, in the present study, we test the hypothesis that specific influences of chronic stressors related to traumatic stress and dissociation are related to alterations in TNF-α levels. We performed psychometric measurement of depression (Beck Depression Inventory [BDI]-II), traumatic stress symptoms (Trauma Symptom Checklist [TSC]-40), and psychological and somatoform dissociation (Dissociative Experiences Scale [DES] and Somatoform Dissociation Questionnaire [SDQ]-20, respectively), and immunochemical measure of serum TNF-α in 66 inpatients with unipolar depression (mean age 43.1 ± 7.3 years). The results show that TNF-α is significantly related to DES (Spearman R=-0.42, P<0.01), SDQ-20 (Spearman R=-0.38, P<0.01), and TSC-40 (Spearman R=-0.41, P<0.01), but not to BDI-II. Results of the present study suggest that TNF-α levels are related to dissociative symptoms and stress exposure in depressed patients.

4.
J Invasive Cardiol ; 25(1): 32-7, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23293173

ABSTRACT

OBJECTIVE: Prediction of coronary atherosclerosis in patients with stable angina based on non-invasive examinations. METHODS: Pro-inflammatory markers, heme oxygenase-1 (HO-1) polymorphism, lipid levels, Framingham risk score (FRS), and carotid ultrasound were analyzed and compared to grayscale and virtual histology intravascular ultrasound (VH-IVUS). RESULTS: A total of 101 patients were included, and genetic analysis was performed on 81 patients (80.2%). The HO-1 risk polymorphism was more frequent in patients post-myocardial infarction (61.3% vs 32%; P=.0097), or with diabetes (68.4% vs 35.5%; P=.011) or a higher FRS (21.5 vs 15.7; P=.014). Plaques in patients with the HO-1 risk polymorphism contained less fibro-fatty tissue (17.1% vs 23.2%; P=.005) and more necrotic core (NC; 17.1% vs 12.7%; P=.02) and calcification (10.2% vs 5.7%; P=.035) compared to patients without the HO-1 risk polymorphism. Carotid intima media thickness (P=.05) and carotid bulb plaque (P=.008) predicted plaque burden. The level of Apo A inversely correlated with NC (P=.047; r = -0.27) and was lower in patients with VH-thin-cap fibroatheroma (VH-TCFA; 1.19 mmol/L vs 1.3 mmol/L; P=.04). FRS correlated with NC (P=.007; r = 0.2), with angiographic disease severity (P=.032; r = 0.21) and was higher in patients with VH-TCFA (9.1 vs 7.8; P=.03). CONCLUSION: Carotid ultrasound and HO-1 polymorphism improve coronary atherosclerosis prediction.


Subject(s)
Angina, Stable , Carotid Artery Diseases/diagnostic imaging , Coronary Artery Disease , Heme Oxygenase-1/genetics , Polymorphism, Genetic , Aged , Angina, Stable/diagnosis , Angina, Stable/genetics , Angina, Stable/pathology , Apolipoproteins A/blood , Biomarkers , Carotid Intima-Media Thickness , Coronary Artery Disease/epidemiology , Coronary Artery Disease/genetics , Coronary Artery Disease/pathology , Female , Genetic Predisposition to Disease/epidemiology , Humans , Male , Middle Aged , Physical Examination , Predictive Value of Tests , Risk Factors
5.
Circ J ; 76(1): 176-83, 2012.
Article in English | MEDLINE | ID: mdl-22076422

ABSTRACT

BACKGROUND: There is no study focusing on changes in coronary atherosclerosis during dual lipid-lowering therapy with statin and ezetimibe. METHODS AND RESULTS: Eighty-nine patients with stable angina randomized in a 1:1 ratio to Group A (aggressive therapy: atorvastatin 80mg, ezetimibe 10mg) and Group S (standard therapy) were analyzed. Treatment period was 12 months. Coronary arteries were examined by intravascular ultrasound and virtual histology. We found a decrease in the percent atheroma volume (PAV) (-0.4%) in Group A compared with an increase (+1.4%) in Group S (P=0.014) and this was accompanied by an increased frequency of combined atherosclerosis regression (increased lumen volume+decreased PAV) in group A (40.5%) compared with group S (14.9%) (P=0.007). The target low-density lipoprotein cholesterol level <2mmol/L, presence of at least 4 of 5 atherosclerotic risk factors, and decreased level of vascular cellular adhesive molecule were independent predictors of plaque regression. There were no significant differences in plaque composition between the 2 groups over the study duration. However, during analysis of the 2 groups together, fibrous and fibro-fatty tissues decreased and dense calcification and necrotic core increased during follow-up. CONCLUSIONS: Dual lipid-lowering therapy starts atherosclerosis regression, but does not lead to significant changes in plaque composition. The continuous shift in plaque from fibro and fibro-fatty to necrotic with calcification was present in both groups.


Subject(s)
Azetidines/therapeutic use , Coronary Artery Disease/drug therapy , Coronary Artery Disease/pathology , Coronary Vessels/pathology , Heptanoic Acids/therapeutic use , Plaque, Atherosclerotic/drug therapy , Plaque, Atherosclerotic/pathology , Pyrroles/therapeutic use , Aged , Anticholesteremic Agents/therapeutic use , Atorvastatin , Cell Adhesion Molecules/metabolism , Cholesterol/metabolism , Coronary Artery Disease/diagnostic imaging , Coronary Vessels/diagnostic imaging , Coronary Vessels/metabolism , Disease Progression , Drug Therapy, Combination , Ezetimibe , Female , Humans , Lipoproteins/metabolism , Male , Middle Aged , Plaque, Atherosclerotic/diagnostic imaging , Single-Blind Method , Treatment Outcome , Ultrasonography, Interventional
6.
Cells Tissues Organs ; 194(6): 469-80, 2011.
Article in English | MEDLINE | ID: mdl-21494018

ABSTRACT

Members of the galectin family of endogenous lectins are potent adhesion/growth-regulatory effectors. Their multifunctionality opens possibilities for their use in bioapplications. We studied whether human galectins induce the conversion of human dermal fibroblasts into myofibroblasts (MFBs) and the production of a bioactive extracellular matrix scaffold is suitable for cell culture. Testing a panel of galectins of all three subgroups, including natural and engineered variants, we detected activity for the proto-type galectin-1 and galectin-7, the chimera-type galectin-3 and the tandem-repeat-type galectin-4. The activity of galectin-1 required the integrity of the carbohydrate recognition domain. It was independent of the presence of TGF-ß1, but it yielded an additive effect. The resulting MFBs, relevant, for example, for tumor progression, generated a matrix scaffold rich in fibronectin and galectin-1 that supported keratinocyte culture without feeder cells. Of note, keratinocytes cultured on this substratum presented a stem-like cell phenotype with small size and keratin-19 expression. In vivo in rats, galectin-1 had a positive effect on skin wound closure 21 days after surgery. In conclusion, we describe the differential potential of certain human galectins to induce the conversion of dermal fibroblasts into MFBs and the generation of a bioactive cell culture substratum.


Subject(s)
Extracellular Matrix/metabolism , Fibroblasts/metabolism , Galectins/metabolism , Myofibroblasts/metabolism , Tissue Engineering/methods , Wound Healing , Animals , Galectin 1/metabolism , Galectin 3/metabolism , Galectin 4/metabolism , Humans , Keratin-19/metabolism , Male , Rats , Transforming Growth Factor beta1/metabolism
7.
Scand J Clin Lab Invest ; 71(2): 157-62, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21247267

ABSTRACT

BACKGROUND: Procalcitonin (PCT) increases in septic patients, and is not transformed into calcitonin (CT). We found in septic patients, a significant increase of CT, as determined by an immunoassay using polyclonal antibodies. We compare determination using polyclonal and monoclonal AB. METHODS: We included 34 patients: 17 with clinical signs of sepsis, a positive haemoculture (PCT > 0.5 µg/L) and 17 without them (PCT < 0.1 µg/L). CT was determined by two above-mentioned methods. The influence on CT levels was observed after using the high-concentration PCT calibrator addition to a mixed serum sample with a low concentration of CT. The dilution test of the high-concentration calibrator PCT was performed by an IBL calibrator, with a zero calcitonin concentration. RESULTS: In the septic patients we found an interference in calcitonin determination using the polyclonal AB (IRMA); 24.1-718 µg/L, proportional to the PCT levels (r = 0.814, p < 0.0001). When using the monoclonal AB (ELISA), the calcitonin levels < 6.5-46.3 ng/L, and no interference of PCT was observed. In the non-septic group, we did not record any PCT interference using either the polyclonal or the monoclonal AB, and the CT levels were within the reference ranges using the two methods (r = 0.997, p < 0.0001). The recovery and dilution tests confirmed interference by PCT on the calcitonin determination with the polyclonal antibody. CONCLUSIONS: Results show that in septic patients there is visible interference of PCT in the calcitonin determination, principally in the IRMA method (polyclonal AB); while no such relationship was observed in the ELISA method (monoclonal AB).


Subject(s)
Calcitonin/analysis , Immunoassay/methods , Protein Precursors/analysis , Antibodies, Monoclonal/immunology , Calcitonin Gene-Related Peptide , Enzyme-Linked Immunosorbent Assay , Humans , Reagent Kits, Diagnostic , Regression Analysis
8.
J Affect Disord ; 120(1-3): 231-4, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19359044

ABSTRACT

BACKGROUND: Recent evidence indicates that various types of interactions between nervous and immune system are important in pathogenesis of depression. These findings show that a significant role in developing depression play pro-inflammatory cytokines that may mediate its psychological, and neurobiological manifestations. Great importance among these cytokine molecules plays interleukin-6 (IL-6). There is growing evidence that this inflammatory process related to depression may be influenced by psychological stress as well as organic inflammatory conditions. These findings suggest that specific influences related to traumatic stress and dissociation could be found in close relationship to increased level of cytokine IL-6. METHODS: In the present study we have performed psychometric measurement of depression (BDI-II), traumatic stress symptoms (TSC-40) and dissociation (DES, SDQ-20), and immunochemical measure of serum IL-6 in 40 inpatients with unipolar depression (mean age 42.3+/-6.8). RESULTS: The results show that IL-6 is significantly correlated to BDI-II (Spearman R=0.47, p<0.01), TSC-40 (Spearman R=0.32, p<0.05), SDQ-20 (Spearman R=0.34, p<0.05) but not to DES (Spearman R=0.25, p=0.11). CONCLUSION: The findings of the present study indicate that increased level of IL-6 in depression could be directly related to symptoms of traumatic stress and somatoform dissociation.


Subject(s)
Depressive Disorder , Interleukin-6/blood , Interleukin-6/immunology , Stress Disorders, Post-Traumatic , Adult , Depressive Disorder/blood , Depressive Disorder/epidemiology , Depressive Disorder/immunology , Dissociative Disorders/blood , Dissociative Disorders/epidemiology , Dissociative Disorders/immunology , Female , Humans , Male , Psychometrics , Severity of Illness Index , Somatoform Disorders/blood , Somatoform Disorders/epidemiology , Somatoform Disorders/immunology , Stress Disorders, Post-Traumatic/blood , Stress Disorders, Post-Traumatic/epidemiology , Stress Disorders, Post-Traumatic/immunology
9.
Tumour Biol ; 28(2): 84-92, 2007.
Article in English | MEDLINE | ID: mdl-17259755

ABSTRACT

BACKGROUND/AIMS: The determination of neuron-specific enolase (NSE) is relatively frequently requested in the differential diagnosis of small-cell lung carcinoma and non-small-cell lung carcinoma. The individual results of different immunoassays are often not comparable, which has been confirmed by long-term external quality assessments. In this study, we assessed the possible sources of these differences. METHODS: More than 3,000 NSE analyses were performed using seven different immunoassays: DELFIA (PerkinElmer), Elecsys 2010 or Modular Analytics E 170 (Roche), Kryptor (B.R.A.H.M.S.), the enzyme-linked immunosorbent assay DRG and three assays based on immunoradiometric assays (DiaSorin, Immunotech and Schering-CIS). The following parameters were evaluated: precision profile of the individual methods, linearity on dilution and modified recovery, comparability and discrimination of immunoassays, sensitivity, and specificity. RESULTS: There were differences in the correlation of values of certain low-concentration specimens. Some assays correlate well while others do not (up to fivefold difference), especially in the case of controls prepared synthetically. Therefore, the current non-standardized preparation of controls is questionable in our opinion. In the cutoff range, the difference in the results of native samples did not exceed its double value. The variation in values >100 microg/l obtained with different assays is <40%. CONCLUSION: Our results confirmed expected matrix interferences especially in the range of normal and cutoff NSE concentrations. Another source of discrepancies can be attributed to different antibody affinity to alphagamma- and gammagamma-enolase isoenzymes. Finally, improper settings of cutoff values also contribute to the different discrimination of the methods.


Subject(s)
Biological Assay , Biomarkers, Tumor/metabolism , Lung Neoplasms/enzymology , Phosphopyruvate Hydratase/blood , Adenocarcinoma/blood , Adenocarcinoma/enzymology , Carcinoma, Large Cell/blood , Carcinoma, Large Cell/enzymology , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/enzymology , Carcinoma, Small Cell/blood , Carcinoma, Small Cell/enzymology , Carcinoma, Squamous Cell/blood , Carcinoma, Squamous Cell/enzymology , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Humans , Lung Neoplasms/blood , Sensitivity and Specificity
10.
Ren Fail ; 28(8): 715-21, 2006.
Article in English | MEDLINE | ID: mdl-17162432

ABSTRACT

BACKGROUND: Dialysis patients are at high risk of vascular/cardiovascular complications with multifactorial pathogenesis, and pregnancy-associated plasma protein A (PAPP-A) is one of the new markers related to cardiovascular risk. Because hemodiafiltration (HDF) is supposed to be better for cardiovascular status, the aim of this study was to describe whether it has any advantage concerning changes of PAPP-A and related molecules during the session in comparison with hemodialysis (HD). METHODS: The studied group consisted of 20 chronic hemodialysis patients. In each patient, PAPP-A and related parameters-IGFBP-4 (insulin like growth factor binding protein), IGF-I (insulin like growth factor), and two MMPs (matrix metalloproteinases)-2 and 9-were determined both during a single online HDF session (high-flux polysulfone membrane HF80, postdilution) and during a single HD session (low-flux polysulfone membrane F6, F7) at time 0 (start), 15 min, 120 min, and 240 min (end) of the session. RESULTS: PAPP-A, elevated at baseline in dialysis patients, changes significantly both during HDF and HD without significant differences between these two procedures (mean levels during HDF were 24.3, 53.9, 24.3, and 27.3 mIU/L). It increases more than two-fold from 0 to 15 min of the session (p < 0.001) and then decreases until the end of the session (p < 0.001). MMP-2 decreased slightly during both sessions (p < 0.001), and changes of other molecules were only minimal. CONCLUSION: A single HDF session compared to HD has no advantage in the decrease of PAPP-A and other tested molecules, all of them related to cardiovascular risk. Studies aimed at a long-term effect of both procedures on these parameters would be needed to further evaluate these therapeutical strategies.


Subject(s)
Hemodiafiltration , Insulin-Like Growth Factor Binding Protein 4/blood , Insulin-Like Growth Factor I/metabolism , Kidney Failure, Chronic/blood , Matrix Metalloproteinase 2/blood , Matrix Metalloproteinase 9/blood , Pregnancy-Associated Plasma Protein-A/metabolism , Adult , Aged , Analysis of Variance , Biomarkers/blood , Cardiovascular Diseases/blood , Cardiovascular Diseases/etiology , Enzyme-Linked Immunosorbent Assay , Female , Fluoroimmunoassay , Hemodiafiltration/adverse effects , Humans , Kidney Failure, Chronic/therapy , Male , Middle Aged , Pregnancy , Renal Dialysis/adverse effects , Time Factors , Treatment Outcome
11.
Clin Chem Lab Med ; 41(8): 1087-94, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12964819

ABSTRACT

MUC1 mucins are tumour markers that are frequently indicated and examined, particularly as part of the treatment of breast cancer. Relatively large differences were observed in external quality assessment (EQA) between the results that were obtained by different immunoassay technologies. Thus, we compared eight routinely employed immunoassay sets for the determination of MUC1 mucins in the serum: six closed automated systems (AxSYM, Centaur, ECi Vitros, Elecsys 2010, Immulite 2000 and Kryptor), and two IRMA kits (ELSA CIS and IRMA-mat Byk-Sangtec). Using all analytical systems, we measured identical groups of clinical samples complete with selected calibrator and control samples. The repeatability of measurements (presented as coefficients of variation) ranged from 0.7% (Kryptor) to 6.9% (Immulite 2000). Even though the cut-off values differ among various systems, no similar clinical efficacy appears to be attained. In the region of cut-off values, the highest specificity that was set as a standard was found for the AxSYM analyser, while the sensitivity was highest for the Elecsys 2010. Data from Bland-Altman differential plots suggest the presence of significant individual differences among individual samples, mainly in the region of high concentrations of MUC1 mucins. The parameters of Passing-Bablok regression show significant systematic differences between some of the analytical systems as well as an increase of the differences with increasing MUC1 mucin concentrations. The effect of the combination of antibodies used on the extent of differences among results obtained with individual systems is more obvious than the effect of the matrix of analysed materials.


Subject(s)
Immunoassay/methods , Mucin-1/blood , Calibration , Data Interpretation, Statistical , Humans , Reproducibility of Results , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...